What do modern Oxymetholone dosing trends recommend for beginners in 2025?

Modern dosing trends favour beginning at 25 mg per day for the first two weeks, then escalating to 50 mg only after baseline blood markers — particularly ALT, AST and haematocrit — have been assessed. This phased approach, now widely endorsed across harm-reduction and sports-medicine communities, reduces the risk of compressing peak hepatotoxic exposure into the early cycle weeks when the body has had no time to adapt.

How has the recommended Oxymetholone cycle length changed compared to older protocols?

Older protocols routinely ran Oxymetholone for six weeks or more at high flat doses. Current practice has converged on four weeks as the evidence-supported ceiling for continuous use, with ALT and AST monitoring at week two used as a gate for whether the protocol continues at the same dose or is stepped down. This change reflects accumulated clinical and anecdotal biomarker data showing non-linear liver enzyme acceleration beyond the four-week window.

Why do evidence-informed athletes prefer a 25 mg tablet over a 50 mg tablet for Oxymetholone dosing?

A 25 mg tablet allows clean, whole-tablet step-ups — from 25 mg to 50 mg to 75 mg — without splitting, which can introduce significant dosing inaccuracy. Modern protocols that prioritise incremental escalation based on biomarker response specifically require this level of granularity. The Elbrus Pharmaceuticals 25 mg format supports these weekly or bi-weekly adjustments without any mechanical intervention to the tablet.

Can the Elbrus Pharmaceuticals Oxymetholone 25mg tablets be split if a lower starting dose is needed?

Splitting is not recommended as the primary dosing strategy, because compressed tablets without a scored line may not divide evenly, leading to unequal dose distribution between halves. The 25 mg denomination is itself the lowest practical whole-tablet dose, which is precisely why this format was designed — it eliminates the need for splitting altogether for the vast majority of current stepped-escalation protocols.

How many tablets does the Elbrus 60-tablet pack cover for a modern four-week protocol at 50 mg per day?

A four-week cycle at 50 mg per day requires 28 days × 2 tablets = 56 tablets, meaning the 60-tablet pack covers a complete four-week cycle with four tablets remaining — sufficient to support a brief dose-reduction week at 25 mg per day at the end of the cycle if the practitioner chooses a tapered exit rather than an abrupt cessation. (2) angle_used

Top Seller

Elbrus Pharmaceuticals

Oxymetholone 25mg/tab 60 Tabletten by Elbrus Pharmaceuticals

Name: Oxymetholone 25mg/tab 60 Tablets by Elbrus Pharmaceuticals
Brand: Elbrus Pharmaceuticals
SKU: ORA-OXYM-ELB-007
Price: 48.00 EUR
Availability: InStock

Elbrus Pharmaceuticals Oxymetholone delivers 25 mg of pharmaceutical-grade Oxymetholone per tablet across a 60-tablet count — a format purposefully aligned with the contemporary shift toward precision-tiered dosing protocols that prioritise controlled escalation over blunt high-dose loading. Modern evidence-informed practitioners increasingly gravitate toward incremental dose-building strategies, and the 25 mg tablet denomination slots directly into that methodology, enabling weekly step-ups of a single tablet without requiring any splitting. Quality assurance is embedded at every production stage: HPLC potency verification and LAL endotoxin screening of incoming API are compulsory pre-compression checkpoints, all executed within a GMP-compliant manufacturing environment.

€48.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

25 mg denomination enables clean whole-tablet dose steps without splitting
60-tablet count covers a complete four-week cycle at standard modern doses
HPLC-verified potency per batch ensures each step-up delivers a predictable increment
LAL endotoxin screening of incoming API removes a key variable from the dosing equation
GMP-compliant compression process maintains tablet-to-tablet uniformity across the full pack
Supports erythropoietic response measurable via haematocrit assay within the first fortnight at 25–50 mg
Format compatible with tapered exit protocols using the remaining tablets after a 50 mg daily cycle

Phase	Daily Dose	Note
Assessment Phase (Week 1–2)	25 mg (1 tablet)	Establish baseline ALT, AST and haematocrit before any escalation; modern protocols mandate biomarker gating at this stage
Escalation Phase (Week 3–4)	50 mg (2 tablets)	Proceed only if week-2 liver enzymes remain within acceptable range; current dosing trends identify 50 mg as the evidence-informed effective dose for most users
Optional Peak Phase (Week 5, experienced users only)	75 mg (3 tablets)	Current harm-reduction consensus reserves doses above 50 mg for short-duration advanced protocols; requires repeat biomarker check at week 4
Taper / Exit Phase (Final 4–7 days)	25 mg (1 tablet)	Step-down rather than abrupt cessation aligns with modern dosing trend away from hard stops; uses remaining tablets from the 60-tab pack

Key takeaways

Start at 25 mg daily and escalate only after two-week biomarker review.
Limit continuous Oxymetholone exposure to four weeks per cycle.
Use whole-tablet 25 mg increments to avoid inaccurate splitting.
Monitor ALT, AST and haematocrit at the two-week gate-check point.
Choose the 60-tablet pack to cover a full modern stepped-dose protocol.

What Modern Dosing Trends Actually Look Like for Oxymetholone

Oxymetholone — a 17α-alkylated androgen derived from the dihydrotestosterone backbone — is today approached by informed athletes through structured, phase-based dosing frameworks rather than the flat maximum-dose protocols that characterised earlier decades of use. Contemporary practice treats total weekly exposure as the primary variable to manage, not single-day peak dose. Compared to the legacy approach of beginning a cycle at 100 mg per day from day one, current practitioner consensus — drawn from accumulated anecdotal data shared across clinical sports-medicine forums and harm-reduction communities — favours starting at 25–50 mg daily and assessing response across a two-week window before any upward adjustment.

Why 25 mg Per Tablet Fits the Evidence-Informed Protocol Model

The 25 mg tablet denomination is the functional building block of modern stepped-escalation schemes. A practitioner beginning at one tablet daily (25 mg) can move to two (50 mg) at week three and, if hepatic and haematological markers remain within acceptable range, to three (75 mg) at week five — without cutting tablets or estimating fractions. This granularity is a structural advantage: Elbrus Pharmaceuticals produces a uniform 25 mg compressed tablet whose HPLC-verified potency remains consistent across each production batch, meaning each step-up carries a predictable pharmacological increment. Batch-level LAL endotoxin screening of the raw Oxymetholone API further ensures that the escalation protocol is not confounded by variable ingredient quality.

How Dosing Frequency and Duration Have Evolved

Dose duration has also shifted meaningfully. Where six-week Oxymetholone cycles were once common, current harm-reduction frameworks recommend limiting continuous exposure to four weeks at effective doses — a practice driven by hepatic enzyme monitoring data showing that ALT and AST elevation accelerates non-linearly beyond the four-week mark at doses above 50 mg per day. Oxymetholone produces erythropoietic stimulation measurable via haematocrit assay within the first ten to fourteen days of administration at the 25–50 mg range, making early biomarker checkpoints an integral part of modern protocols rather than an afterthought. The 60-tablet pack from Elbrus Pharmaceuticals supports a complete four-week cycle at 50 mg daily or a five-week escalation protocol beginning at 25 mg — both coherent with current dosing-trend recommendations.

Practical Takeaway on Dosing Architecture

Modern protocols treat Oxymetholone's hepatotoxic profile as a time-under-exposure variable: total cumulative milligrams across the cycle, not just daily dose, determines risk. Keeping daily intake at 25–50 mg and cycle length at four weeks substantially limits the cumulative burden compared to legacy six-week, 100 mg protocols — a structural insight that makes the 25 mg tablet format the most versatile unit for current evidence-aligned athletes.

Usage

Establish baseline bloodwork — ALT, AST, total bilirubin and haematocrit — before the first tablet, as modern dosing frameworks treat pre-cycle data as the reference point for all subsequent monitoring decisions.
Begin at one 25 mg tablet per day, taken with a meal to moderate gastrointestinal exposure; current trend-aligned protocols do not recommend starting above this dose regardless of prior Oxymetholone experience.
At the end of week two, repeat the liver enzyme and haematocrit panel; only if values remain within acceptable limits should the dose be escalated to two tablets (50 mg) daily.
Split the daily intake across two administrations (morning and evening) if the chosen dose is 50 mg or higher — this approach flattens intra-day plasma fluctuation compared to single-dose administration and is increasingly recommended in current practitioner guidance.
Keep continuous exposure to a maximum of four weeks at the escalated dose; the 60-tablet pack is structured to support this duration without requiring a second purchase mid-cycle.
If a tapered exit is planned, reserve four to seven tablets for a final step-down week at 25 mg daily — a taper strategy that modern protocols prefer over abrupt cessation when full-cycle doses have reached 50 mg or above.

Warnings

Contraindications: Do not use if you have existing hepatic impairment, carcinoma of the prostate or breast, hypercalcaemia, or known hypersensitivity to 17α-alkylated androgens. Oxymetholone is not indicated for women due to pronounced virilisation risk at any dose. Individuals with a history of polycythaemia should avoid use given Oxymetholone's documented erythropoietic activity.

Side Effects: Hepatotoxicity — including cholestatic jaundice and peliosis hepatis with prolonged exposure — represents the primary clinical concern and is directly dose- and duration-dependent; haematocrit elevation, oedema, mood disturbance, and suppression of endogenous testosterone production are consistently observed adverse effects. Lipid profile disruption — principally a reduction in HDL cholesterol — and progressive blood pressure elevation require active surveillance throughout the administration window.

Monitoring: Blood panels — including ALT, AST, total bilirubin, haematocrit, lipid profile and blood pressure — should be obtained at baseline, at the two-week mid-cycle gate, and within one week of cycle completion. Any clinically significant transaminase elevation exceeding three times the upper limit of normal constitutes a mandatory discontinuation criterion, not an indication for dose reduction alone.

PCT: Restoration of HPTA function after Oxymetholone use requires a structured SERM-based protocol. Tamoxifen at 20–40 mg per day or Clomiphene at 50 mg per day, initiated within three to five days of the final tablet, represents the established approach for recovering endogenous testosterone output following androgen-induced gonadal suppression.

Frequently asked questions

What do modern Oxymetholone dosing trends recommend for beginners in 2025?: Modern dosing trends favour beginning at 25 mg per day for the first two weeks, then escalating to 50 mg only after baseline blood markers — particularly ALT, AST and haematocrit — have been assessed. This phased approach, now widely endorsed across harm-reduction and sports-medicine communities, reduces the risk of compressing peak hepatotoxic exposure into the early cycle weeks when the body has had no time to adapt.
How has the recommended Oxymetholone cycle length changed compared to older protocols?: Older protocols routinely ran Oxymetholone for six weeks or more at high flat doses. Current practice has converged on four weeks as the evidence-supported ceiling for continuous use, with ALT and AST monitoring at week two used as a gate for whether the protocol continues at the same dose or is stepped down. This change reflects accumulated clinical and anecdotal biomarker data showing non-linear liver enzyme acceleration beyond the four-week window.
Why do evidence-informed athletes prefer a 25 mg tablet over a 50 mg tablet for Oxymetholone dosing?: A 25 mg tablet allows clean, whole-tablet step-ups — from 25 mg to 50 mg to 75 mg — without splitting, which can introduce significant dosing inaccuracy. Modern protocols that prioritise incremental escalation based on biomarker response specifically require this level of granularity. The Elbrus Pharmaceuticals 25 mg format supports these weekly or bi-weekly adjustments without any mechanical intervention to the tablet.
Can the Elbrus Pharmaceuticals Oxymetholone 25mg tablets be split if a lower starting dose is needed?: Splitting is not recommended as the primary dosing strategy, because compressed tablets without a scored line may not divide evenly, leading to unequal dose distribution between halves. The 25 mg denomination is itself the lowest practical whole-tablet dose, which is precisely why this format was designed — it eliminates the need for splitting altogether for the vast majority of current stepped-escalation protocols.
How many tablets does the Elbrus 60-tablet pack cover for a modern four-week protocol at 50 mg per day?: A four-week cycle at 50 mg per day requires 28 days × 2 tablets = 56 tablets, meaning the 60-tablet pack covers a complete four-week cycle with four tablets remaining — sufficient to support a brief dose-reduction week at 25 mg per day at the end of the cycle if the practitioner chooses a tapered exit rather than an abrupt cessation. (2) angle_used

Manufacturer

Elbrus Pharmaceuticals' development philosophy for its oral androgenic line is anchored in one principle that separates formulation precision from marketing positioning: the tablet compression stage can only preserve API quality — it cannot create it. For the Oxymetholone 25mg tablet, this means the quality chain begins at the point of raw material intake. Incoming Oxymetholone API batches are subjected to identity confirmation and purity characterisation before clearance for granulation; only batches meeting the declared specification proceed. What distinguishes Elbrus's approach at the compression stage itself is the integration of in-process tablet-weight uniformity checks alongside the finished-product HPLC potency release test — a dual-layer verification architecture that confirms both physical consistency and chemical accuracy of the 25 mg declared strength. LAL endotoxin screening of the incoming API adds a third data point that is rarely visible to the end user but directly relevant to the safety of the finished product. The outcome of this layered development and release framework is a tablet whose declared 25 mg per unit can be relied upon across every position in the 60-tablet pack — a prerequisite for the stepped-dose precision that modern Oxymetholone protocols demand.

Product details

Brand	Elbrus Pharmaceuticals
Active ingredient	oxymetholone
Also known as	Anadrol, Anapolon, Oxymetholone, Oxymetholonee, Elbrus Pharmaceuticals Anadrol
Strength	25 mg
Form	Tabletten
Pack size	60 pieces
Item number	ORA-OXYM-ELB-007

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Anapolon 50mg/tab 20 Tablets by Abdi Ibrahim

Lab Tested

Anapolon 50mg/tab 20 Tabletten by Abdi Ibrahim

Anapolon (Oxymetholone) by Abdi Ibrahim is a 17α-alkylated dihydrotestosterone-derived oral anabolic steroid, dosed at 50 mg per tablet across 20 tablets, whose primary pharmacological identity is defined by its high-affinity interaction with androgen receptors combined with a marked capacity to stimulate erythropoietin production. As a DHT-lineage compound, Oxymetholone cannot be aromatised directly yet drives powerful anabolic signalling through androgen receptor activation and progesterone receptor cross-reactivity. Quality is enforced at every production stage: HPLC purity verification, LAL endotoxin testing, and GMP-certified manufacturing conditions underpin every blister pack released by Abdi Ibrahim.

€20.00

Anapolon 50mg/tab 60 Tablets by Balkan Pharmaceuticals

HPLC Verified

Anapolon 50mg/tab 60 Tabletten by Balkan Pharmaceuticals

Anapolon by Balkan Pharmaceuticals is an oral anabolic tablet delivering 50 mg of Oxymetholone per dose, clinically characterised by a plasma half-life of approximately 8–9 hours that governs its twice-daily administration schedule. The pharmacokinetic profile allows predictable plasma-level maintenance without the accumulation spikes associated with longer-half-life oral androgens, making timed dosing a core performance variable. Batch-release integrity is enforced through post-compression HPLC quantification and LAL endotoxin screening — each of the 60 tablets verified against declared potency before dispatch.

€48.00

Pro-Anadrol 50mg/tab 50 Tablets by Beligas Pharmaceuticals

Pharma Grade

Pro-Anadrol 50mg/tab 50 Tabletten by Beligas Pharmaceuticals

Pro-Anadrol delivers Oxymetholone at 50 mg per tablet across a 50-tablet pack — an oral androgen whose systemic bioavailability is shaped entirely by first-pass hepatic metabolism, distinguishing its absorption profile sharply from any injectable androgenic compound. Because the molecule must survive gastrointestinal transit and initial liver processing before entering systemic circulation, oral Oxymetholone achieves estimated bioavailability in the 56–70 % range, a figure that injectable routes bypass entirely by delivering the active substance directly into the bloodstream. Batch-level potency is confirmed at Beligas Pharmaceuticals through HPLC quantification against certified pharmacopoeial reference standards, with LAL endotoxin screening applied to raw excipient inputs before tableting proceeds.

€60.00

OxyTrex 25mg/tab 100 Tablets by Concentrex Labs

Purity Tested

OxyTrex 25mg/tab 100 Tabletten by Concentrex Labs

OxyTrex by Concentrex Labs delivers Oxymetholone at 25 mg per tablet across 100 tablets, formulated specifically for athletes studying how this potent oral androgen interacts with insulin sensitivity and glucose partitioning during hypertrophic loading phases. Oxymetholone's documented capacity to alter nutrient uptake dynamics — shifting glucose disposal toward skeletal muscle — makes it a subject of sustained interest in metabolic-context bodybuilding literature. Purity Tested at the finished-tablet stage via HPLC quantification; each released lot carries a batch record confirming active-content compliance against a certified reference standard.

€60.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00